Abstract
Summary
Nucleic acid medicines utilize nucleic acid, which refer to substances such as DNA and RNA that control genetic information, as drugs. These allow targeting of molecules such as mRNA and miRNA that cannot be targeted with traditional low molecular weight drugs and antibody medicines, and there is a great expectation for these drugs as next generation pharmaceuticals. Active research is being conducted globally as it is expected to lead to the creation of drugs which were previously intractable.
LPI (LP Information)' newest research report, the “Nucleic Acid Medicine Industry Forecast” looks at past sales and reviews total world Nucleic Acid Medicine sales in 2022, providing a comprehensive analysis by region and market sector of projected Nucleic Acid Medicine sales for 2023 through 2029. With Nucleic Acid Medicine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Nucleic Acid Medicine industry.
This Insight Report provides a comprehensive analysis of the global Nucleic Acid Medicine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Nucleic Acid Medicine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Nucleic Acid Medicine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Nucleic Acid Medicine and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Nucleic Acid Medicine.
The global Nucleic Acid Medicine market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Nucleic Acid Medicine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Nucleic Acid Medicine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Nucleic Acid Medicine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Nucleic Acid Medicine players cover Novartis, Ionis, Nippon Shinyaku, Alnylam, Sarepta Therapeutics, MiNA Therapeutics, BioNTech and Moderna, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Nucleic Acid Medicine market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
ASO
siRNA
Other
Segmentation by application
Cardiovascular Diseases
Hepatitis B
Hypertension
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis
Ionis
Nippon Shinyaku
Alnylam
Sarepta Therapeutics
MiNA Therapeutics
BioNTech
Moderna
Key Questions Addressed in this Report
What is the 10-year outlook for the global Nucleic Acid Medicine market?
What factors are driving Nucleic Acid Medicine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Nucleic Acid Medicine market opportunities vary by end market size?
How does Nucleic Acid Medicine break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
LPI (LP Information)' newest research report, the “Nucleic Acid Medicine Industry Forecast” looks at past sales and reviews total world Nucleic Acid Medicine sales in 2022, providing a comprehensive analysis by region and market sector of projected Nucleic Acid Medicine sales for 2023 through 2029. With Nucleic Acid Medicine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Nucleic Acid Medicine industry.
This Insight Report provides a comprehensive analysis of the global Nucleic Acid Medicine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Nucleic Acid Medicine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Nucleic Acid Medicine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Nucleic Acid Medicine and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Nucleic Acid Medicine.
The global Nucleic Acid Medicine market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Nucleic Acid Medicine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Nucleic Acid Medicine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Nucleic Acid Medicine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Nucleic Acid Medicine players cover Novartis, Ionis, Nippon Shinyaku, Alnylam, Sarepta Therapeutics, MiNA Therapeutics, BioNTech and Moderna, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Nucleic Acid Medicine market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
ASO
siRNA
Other
Segmentation by application
Cardiovascular Diseases
Hepatitis B
Hypertension
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis
Ionis
Nippon Shinyaku
Alnylam
Sarepta Therapeutics
MiNA Therapeutics
BioNTech
Moderna
Key Questions Addressed in this Report
What is the 10-year outlook for the global Nucleic Acid Medicine market?
What factors are driving Nucleic Acid Medicine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Nucleic Acid Medicine market opportunities vary by end market size?
How does Nucleic Acid Medicine break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Nucleic Acid Medicine Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Nucleic Acid Medicine by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Nucleic Acid Medicine by Country/Region, 2018, 2022 & 2029
2.2 Nucleic Acid Medicine Segment by Type
2.2.1 ASO
2.2.2 siRNA
2.2.3 Other
2.3 Nucleic Acid Medicine Sales by Type
2.3.1 Global Nucleic Acid Medicine Sales Market Share by Type (2018-2023)
2.3.2 Global Nucleic Acid Medicine Revenue and Market Share by Type (2018-2023)
2.3.3 Global Nucleic Acid Medicine Sale Price by Type (2018-2023)
2.4 Nucleic Acid Medicine Segment by Application
2.4.1 Cardiovascular Diseases
2.4.2 Hepatitis B
2.4.3 Hypertension
2.4.4 Other
2.5 Nucleic Acid Medicine Sales by Application
2.5.1 Global Nucleic Acid Medicine Sale Market Share by Application (2018-2023)
2.5.2 Global Nucleic Acid Medicine Revenue and Market Share by Application (2018-2023)
2.5.3 Global Nucleic Acid Medicine Sale Price by Application (2018-2023)
3 Global Nucleic Acid Medicine by Company
3.1 Global Nucleic Acid Medicine Breakdown Data by Company
3.1.1 Global Nucleic Acid Medicine Annual Sales by Company (2018-2023)
3.1.2 Global Nucleic Acid Medicine Sales Market Share by Company (2018-2023)
3.2 Global Nucleic Acid Medicine Annual Revenue by Company (2018-2023)
3.2.1 Global Nucleic Acid Medicine Revenue by Company (2018-2023)
3.2.2 Global Nucleic Acid Medicine Revenue Market Share by Company (2018-2023)
3.3 Global Nucleic Acid Medicine Sale Price by Company
3.4 Key Manufacturers Nucleic Acid Medicine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Nucleic Acid Medicine Product Location Distribution
3.4.2 Players Nucleic Acid Medicine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Nucleic Acid Medicine by Geographic Region
4.1 World Historic Nucleic Acid Medicine Market Size by Geographic Region (2018-2023)
4.1.1 Global Nucleic Acid Medicine Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Nucleic Acid Medicine Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Nucleic Acid Medicine Market Size by Country/Region (2018-2023)
4.2.1 Global Nucleic Acid Medicine Annual Sales by Country/Region (2018-2023)
4.2.2 Global Nucleic Acid Medicine Annual Revenue by Country/Region (2018-2023)
4.3 Americas Nucleic Acid Medicine Sales Growth
4.4 APAC Nucleic Acid Medicine Sales Growth
4.5 Europe Nucleic Acid Medicine Sales Growth
4.6 Middle East & Africa Nucleic Acid Medicine Sales Growth
5 Americas
5.1 Americas Nucleic Acid Medicine Sales by Country
5.1.1 Americas Nucleic Acid Medicine Sales by Country (2018-2023)
5.1.2 Americas Nucleic Acid Medicine Revenue by Country (2018-2023)
5.2 Americas Nucleic Acid Medicine Sales by Type
5.3 Americas Nucleic Acid Medicine Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Nucleic Acid Medicine Sales by Region
6.1.1 APAC Nucleic Acid Medicine Sales by Region (2018-2023)
6.1.2 APAC Nucleic Acid Medicine Revenue by Region (2018-2023)
6.2 APAC Nucleic Acid Medicine Sales by Type
6.3 APAC Nucleic Acid Medicine Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Nucleic Acid Medicine by Country
7.1.1 Europe Nucleic Acid Medicine Sales by Country (2018-2023)
7.1.2 Europe Nucleic Acid Medicine Revenue by Country (2018-2023)
7.2 Europe Nucleic Acid Medicine Sales by Type
7.3 Europe Nucleic Acid Medicine Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Nucleic Acid Medicine by Country
8.1.1 Middle East & Africa Nucleic Acid Medicine Sales by Country (2018-2023)
8.1.2 Middle East & Africa Nucleic Acid Medicine Revenue by Country (2018-2023)
8.2 Middle East & Africa Nucleic Acid Medicine Sales by Type
8.3 Middle East & Africa Nucleic Acid Medicine Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Nucleic Acid Medicine
10.3 Manufacturing Process Analysis of Nucleic Acid Medicine
10.4 Industry Chain Structure of Nucleic Acid Medicine
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Nucleic Acid Medicine Distributors
11.3 Nucleic Acid Medicine Customer
12 World Forecast Review for Nucleic Acid Medicine by Geographic Region
12.1 Global Nucleic Acid Medicine Market Size Forecast by Region
12.1.1 Global Nucleic Acid Medicine Forecast by Region (2024-2029)
12.1.2 Global Nucleic Acid Medicine Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Nucleic Acid Medicine Forecast by Type
12.7 Global Nucleic Acid Medicine Forecast by Application
13 Key Players Analysis
13.1 Novartis
13.1.1 Novartis Company Information
13.1.2 Novartis Nucleic Acid Medicine Product Portfolios and Specifications
13.1.3 Novartis Nucleic Acid Medicine Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Novartis Main Business Overview
13.1.5 Novartis Latest Developments
13.2 Ionis
13.2.1 Ionis Company Information
13.2.2 Ionis Nucleic Acid Medicine Product Portfolios and Specifications
13.2.3 Ionis Nucleic Acid Medicine Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Ionis Main Business Overview
13.2.5 Ionis Latest Developments
13.3 Nippon Shinyaku
13.3.1 Nippon Shinyaku Company Information
13.3.2 Nippon Shinyaku Nucleic Acid Medicine Product Portfolios and Specifications
13.3.3 Nippon Shinyaku Nucleic Acid Medicine Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Nippon Shinyaku Main Business Overview
13.3.5 Nippon Shinyaku Latest Developments
13.4 Alnylam
13.4.1 Alnylam Company Information
13.4.2 Alnylam Nucleic Acid Medicine Product Portfolios and Specifications
13.4.3 Alnylam Nucleic Acid Medicine Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Alnylam Main Business Overview
13.4.5 Alnylam Latest Developments
13.5 Sarepta Therapeutics
13.5.1 Sarepta Therapeutics Company Information
13.5.2 Sarepta Therapeutics Nucleic Acid Medicine Product Portfolios and Specifications
13.5.3 Sarepta Therapeutics Nucleic Acid Medicine Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Sarepta Therapeutics Main Business Overview
13.5.5 Sarepta Therapeutics Latest Developments
13.6 MiNA Therapeutics
13.6.1 MiNA Therapeutics Company Information
13.6.2 MiNA Therapeutics Nucleic Acid Medicine Product Portfolios and Specifications
13.6.3 MiNA Therapeutics Nucleic Acid Medicine Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 MiNA Therapeutics Main Business Overview
13.6.5 MiNA Therapeutics Latest Developments
13.7 BioNTech
13.7.1 BioNTech Company Information
13.7.2 BioNTech Nucleic Acid Medicine Product Portfolios and Specifications
13.7.3 BioNTech Nucleic Acid Medicine Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 BioNTech Main Business Overview
13.7.5 BioNTech Latest Developments
13.8 Moderna
13.8.1 Moderna Company Information
13.8.2 Moderna Nucleic Acid Medicine Product Portfolios and Specifications
13.8.3 Moderna Nucleic Acid Medicine Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Moderna Main Business Overview
13.8.5 Moderna Latest Developments
14 Research Findings and Conclusion